SCHEMBL1109788

SCHEMBL1109788

CN(Cc1ccc(CCO)cc1)C(=O)OC(C)(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 2/20 0.49
CYP4F2 P78329 3/20 0.42
CYP4A11 Q02928 3/20 0.42
CTSL P07711 1/20 0.42
CTSB P07858 1/20 0.42
CTSS P25774 1/20 0.42
KMT2A Q03164 1/20 0.41
HTR2C P28335 1/20 0.40
SLC6A4 P31645 1/20 0.40
RIPK1 Q13546 2/20 0.40
GLS O94925 1/20 0.40
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
NCOR2 Q9Y618 1/20 0.38
ALDH1A1 P00352 3/20 0.38
HTT P42858 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
RAB9A P51151 2/20 0.37
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24542518 0.91 PPARA (0.51) PPARACYP4F2CYP4A11CTSLCTSB
SCHEMBL1935308 0.87 PPARG (0.46) PPARACTSLCTSBCTSSHTR2C
SCHEMBL2318201 0.86 ACHE (0.41) CTSLCTSBCTSSKMT2AHTR2C
SCHEMBL23448763 0.85 HRH3 (0.44) CTSLCTSBCTSSHTR2CSLC6A4
SCHEMBL29086461 0.85 KMT2A (0.49) KMT2AHTR2CSLC6A4HTTRAB9A
SCHEMBL24542516 0.85 KMT2A (0.45) CYP4F2CYP4A11CTSLCTSBCTSS
SCHEMBL25546128 0.84 HSP90AA1 (0.43) CTSLCTSBCTSSHTR2CSLC6A4
SCHEMBL2229917 0.84 MTOR (0.48) CTSLCTSBCTSSHTR2CSLC6A4
SCHEMBL29743546 0.84 PPARA (0.45) PPARACYP4F2CYP4A11CTSLCTSB
SCHEMBL24542515 0.84 GLS (0.42) PPARACTSLCTSBCTSSKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115666575-B Compounds and uses thereof 福宏治疗公司 2024-12-10 CN disclosed
US-20230150974-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
EP-4132529-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2023-02-15 EP disclosed
US-20120277275-A1 AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) 2012-11-01 US disclosed
US-20120277275-A1 AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) 2012-11-01 US disclosed
US-20120277275-A1 AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) 2012-11-01 US disclosed
EP-2280006-A1 PHARMACEUTICAL COMPOSITION FOR INHALATION COMPRISING AN OXAZOLE OR THIAZOLE M3 MUSCARINIC RECEPTOR ANTAGONIST Pulmagen Therapeutics (Synergy) Limited (GB) 2011-02-02 EP disclosed
EP-2280006-A1 PHARMACEUTICAL COMPOSITION FOR INHALATION COMPRISING AN OXAZOLE OR THIAZOLE M3 MUSCARINIC RECEPTOR ANTAGONIST Pulmagen Therapeutics (Synergy) Limited (GB) 2011-02-02 EP disclosed
EP-1924570-B1 AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE PULMAGEN THERAPEUTICS SYNERGY (GB) 2010-10-20 EP disclosed
US-20100216758-A1 Pyridone Compounds MSD K.K. (JP) 2010-08-26 US disclosed
US-20100113540-A1 Azole and Thiazole Derivatives and Their Use ARGENTA DISCOVERY LIMITED (GB) 2010-05-06 US disclosed
US-20100113540-A1 Azole and Thiazole Derivatives and Their Use ARGENTA DISCOVERY LIMITED (GB) 2010-05-06 US disclosed
US-20100113540-A1 Azole and Thiazole Derivatives and Their Use ARGENTA DISCOVERY LIMITED (GB) 2010-05-06 US disclosed
WO-2007017669-A1 AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE ARGENTA DISCOVERY LTD. (GB) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113540-A1 Azole and Thiazole Derivatives and Their Use CHRM3, CHRM2, CHRM1 PPARA 325/4885CYP4F2 695/4885CYP4A11 374/4885
US-20100216758-A1 Pyridone Compounds NPY1R, MC5R, MC1R PPARA 1244/4885CYP4F2 381/4885CYP4A11 409/4885
US-20230150974-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB PPARA 1483/4885CYP4F2 2084/4885CYP4A11 2926/4885
US-20120277275-A1 AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE CHRM3, GPR65, GPR34 PPARA 309/4885CYP4F2 280/4885CYP4A11 275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.